18 and older, any sex, with Coronavirus. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Success of Administering PlasmaPrimary· At time of administration
Number of patients who receive convalescent plasma
Group
Value
95% CI
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
10
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
0
Type of Respiratory SupportPrimary· Until discharge from hospital
Levels of respiratory support will be graded (e.g. room air, high flow oxygen, intubation) to determine the change in type of respiratory support at 28 days.
At time of administration
Group
Value
95% CI
Plasma Recipients
2
Plasma Recipients
1
Plasma Recipients
1
Plasma Recipients
5
At time of discharge
Group
Value
95% CI
Plasma Recipients
0
Plasma Recipients
0
Plasma Recipients
0
Plasma Recipients
3
Cardiac ArrestSecondary· 28 days after plasma administration
Number of patients experiencing cardiac arrest.
Group
Value
95% CI
Plasma Recipient
0
Plasma Recipient
10
Transfer to ICUSecondary· 28 days
Number of patients transferred to ICU
Group
Value
95% CI
Plasma Recipient
1
Plasma Recipient
5
Plasma Recipient
1
Plasma Recipient
3
ICU MortalitySecondary· Until discharge
Number of patients dying in the ICU
Group
Value
95% CI
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
2
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
5
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
3
ICU Length of StaySecondary· Up to 50 days
This will be a continuous outcome defined by the amount of time between plasma administration and discharge from ICU. This will be treated as a time-to-event.
Group
Value
95% CI
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
20
2 – 50
Hospital MortalitySecondary· Until discharge
Mortality during course of illness
Group
Value
95% CI
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
2
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
8
Hospital Length of StaySecondary· Until discharge
This will be a continuous outcome defined by the amount of time between plasma administration and discharge from hospital.
Group
Value
95% CI
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
36.2
32 – 50
Ventilator-free DaysSecondary· 28 days
This will be a continuous outcome defined by the amount of time between plasma administration and the transition from mechanical ventilation to non-invasive respiratory support.
Group
Value
95% CI
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
21.7
0 – 28
Overall Survival (28-day Mortality)Secondary· 28 days
28-Day Overall Survival is defined as the status of the patient at the end of 28 days, beginning from the time of plasma administration.
Group
Value
95% CI
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
0
Treatment With Anti-SARS-CoV-2 Convalescent Plasma
10
Sponsor's own description
The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19.
Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and could be rapidly available when there are sufficient numbers of people who have recovered and can donate high titer neutralizing immunoglobulin-containing plasma.
Hypothesis: Collecting and administering convalescent plasma requires a level of logistical coordination that is not available in all centers.
Objective: To establish feasibility for a hospital-based integrated system to collect and administer convalescent plasma to patients with severe or life-threatening COVID-19.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
· recruiting
NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
· NA
· recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection
· recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults
· Phase 3
· recruiting
NCT04568148 — COVID-19 Biorepository
· active not recruiting
Other University of Chicago trials
Trials by the same sponsor.
NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
· Phase 2
· not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
· Phase 1, PHASE2
· not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
· NA
· not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr
· Phase 2
· not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04340050.